Cargando…
Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis
GM1-gangliosidosis is a progressive neurodegenerative glycosphingolipidosis resulting from a GLB1 gene mutation causing a deficiency of the lysosomal enzyme β-galactosidase, which leads to the abnormal accumulation of GM1 ganglioside in the central nervous system. In the most severe early infantile...
Autores principales: | Tsunogai, Toshiki, Ohashi, Toya, Shimada, Yohta, Higuchi, Takashi, Kimura, Ayaka, Watabe, Ayako M., Kato, Fusao, Ida, Hiroyuki, Kobayashi, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118356/ https://www.ncbi.nlm.nih.gov/pubmed/35615711 http://dx.doi.org/10.1016/j.omtm.2022.04.012 |
Ejemplares similares
-
Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis
por: Tsunogai, Toshiki, et al.
Publicado: (2022) -
GM1 Gangliosidosis—A Mini-Review
por: Nicoli, Elena-Raluca, et al.
Publicado: (2021) -
Genetics and Therapies for GM2 Gangliosidosis
por: Cachón-González, María Begoña, et al.
Publicado: (2018) -
GM1 Gangliosidosis: Mechanisms and Management
por: Rha, Allisandra K, et al.
Publicado: (2021) -
Preclinical Enzyme Replacement Therapy with a Recombinant β-Galactosidase-Lectin Fusion for CNS Delivery and Treatment of GM1-Gangliosidosis
por: Weesner, Jason Andrew, et al.
Publicado: (2022)